U Un nu us su ua al l m ma an ni if fe es st ta at ti io on ns s o of f g gi ia an nt t c ce el ll l a ar rt te er ri it ti is s: : p pu ul lm mo on na ar ry y n no od du ul le es s, , c co ou ug gh h, , c co on nj ju un nc ct ti iv vi it ti is s a an nd d o ot ti it ti is s w wi it th h d de ea af fn ne es ss s T. Zenone*, P-J. Souquet*, C. Bohas*, D. Vital Durand**, J-P. Bernard* We conclude that overlapping features of giant cell arteritis and Wegener's granulomatosis occur in some patients.
Introduction: Prison inmates are known to be more exposed to various lung cancer risk factors, and some studies have shown that lung cancer is the most common cancer in prisoners. However, no study has particularly focused on lung cancer features in this population. Method: Charts of patients with lung cancer hospitalized in one of the French secured hospital units between 1997 and 2012 were reviewed. Data from this cohort were then compared to those of two large observational studies conducted in 2000 and 2010 (KBP studies). Results: Thirty-two cases were included. All were men. The mean age was 52.2 ± 11.5 years, which was significantly lower than in the KBP-2000 (64.4 years) and KBP-2010 (65.5 years; both p < 0.0001) studies. The percentage of current smokers was much higher in prisoners (87.1 vs. 52.2 and 49.2%, respectively; both p < 0.001). Ninety percent of prisoners presented with at least one comorbidity. Lung cancer clinical presentation did not differ between prisoners and the reference populations. The median overall survival was 5.8 months (range 0-15.1) for all stages and 4.7 months (range 2.8-6.6) for stage IIIB/IV. Conclusion: Although our study suffers from limitations, prisoners seem to develop lung cancer at a younger age and their prognosis is poor.
After reviewing 1039 records, 17 PS-adjusted studies with a total of 20151 patients were included in the final analysis. Overall survival (OS) favored surgery over SABR (HR ¼ 1.52 [95% CI: 1.33-1.74], p <0.001). However, the rate at which patients died from lung cancer (DSS) was not significantly different (HR ¼ 1.13 [95% CI: 0.86-1.49], p ¼ 0.38). On subgroup analysis, OS was superior for both lobectomy (HR ¼ 1.61 [95% CI: 1.27-2.03], p <0.001) and sublobar resection (HR ¼ 1.33 [95% CI: 1.15-1.55], p <0.001) versus SABR while DSS again did not significantly differ (HR ¼ 1.35 [95% CI: 0.70-2.62] and HR ¼ 1.18 [95% CI: 0.84-1.67], respectively). On secondary analysis, meta-analysis of proportions revealed a lymph node upstaging rate of 16.0% (95% CI: 13.6%-18.6%) and adjuvant chemotherapy usage rate of 11.5% (95% CI: 8.6%-14.8%) among patients who received surgery. On metaregression, with every increase of 0.1 in the maximum allowable difference in propensity score within a matched pair-representing increases in imbalance between cohorts, DSS outcomes increasingly favored surgery by 1.36-fold. Critical appraisal revealed inconsistent reporting of propensity score methods. Conclusion: Overall survival favored surgery over SABR in this meta-analysis of 17 propensity score analyses. However, the effectiveness of SABR was reflected in a similar DSS to surgery, supporting ongoing clinical equipoise. A direct relationship between propensity score methodology and DSS outcomes were demonstrated. Whether this observed benefit in OS for surgery is real or due to limitations in the propensity score methodology requires confirmation through randomized data.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.